Merck
  • Home
  • Search Results
  • Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.

Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.

American journal of otolaryngology (2015-11-08)
Feng Liu, JinTao Du, Junming Xian, Yafeng Liu, Shixi Liu, Yan Lin
ABSTRACT

The tumor suppressor p14(ARF) and proto-oncogene epidermal growth factor receptor (EGFR) play important roles in the development of laryngeal squamous cell carcinoma (LSCC). This study was aimed to determine whether combining recombinant p14(ARF) with antisense complementary DNA of EGFR could improve the therapeutic effectiveness in LSCC. After human larynx cancer cells (Hep-2) were infected with recombinant adenoviruses (Ad-p14(ARF) and Ad-antisense EGFR) together or alone in vitro, the proliferation and cell cycle distribution of Hep-2 cells were detected by MTT assay and flow cytometer analysis, respectively. Furthermore, the antitumor effects of recombinant adenoviruses together or alone on Hep-2 xenografts were examined in vivo. The levels of p14(ARF) and EGFR expressed in Hep-2 cells and xenografts were determined by western blot assay. Ad-p14(ARF) combining with Ad-antisense EGFR markedly inhibited the Hep-2 proliferation compared with alone (P=0.001, P=0.002 respectively). Combination of Ad-p14(ARF) and Ad-antisense EGFR led to the proportion of Hep-2 cells in G0/G1 phases increased by up to 86.9%. The down-expression of EGFR protein and overexpression of p14(ARF) protein were observed in vitro and in vivo, and this effect was preserved when Ad-p14(ARF) was combined with Ad-antisense EGFR. Besides, Ad-p14(ARF) plus Ad-antisense EGFR significantly (P<0.05) increased the antitumor activity against Hep-2 tumor xenografts comparing with Ad-p14(ARF) or Ad-antisense EGFR alone. Combination Ad-p14(ARF) with Ad-antisense EGFR significantly increased the antitumor responses in LSCC. An effectively potential gene therapy to prevent proliferation of LSCC was provided.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Sigma-Aldrich
Glycerol solution, puriss. p.a., 86-89% (T)
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerol, ≥99.5%
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Glycerol, for molecular biology, ≥99.0%
Sigma-Aldrich
Cesium chloride, BioXtra, ≥99.5% (titration)
Sigma-Aldrich
Cesium chloride, for molecular biology, ≥98%
Sigma-Aldrich
Cesium chloride, optical grade, ≥99.5% trace metals basis
Sigma-Aldrich
Cesium chloride, Grade I, ≥99.0%
Sigma-Aldrich
Cesium chloride, Grade II, ≥98%
Sigma-Aldrich
Cesium chloride, for molecular biology, ≥99% (silver nitrate titration)
Sigma-Aldrich
Cesium chloride, 99.99% trace metals basis
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Cesium chloride, ≥99.999% trace metals basis
Sigma-Aldrich
Cesium chloride, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Cesium chloride, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Glycerol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glycerol, Vetec, reagent grade, 99%
Sigma-Aldrich
Glycerol, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E422, anhydrous, 99.0-101.0% (alkalimetric)
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glycerol, ACS reagent, ≥99.5%
Sigma-Aldrich
Cesium chloride, ReagentPlus®, 99.9%
Sigma-Aldrich
Cesium chloride, puriss. p.a., ≥99.5%
Sigma-Aldrich
Glycerol, puriss. p.a., ACS reagent, anhydrous, dist., ≥99.5% (GC)
Sigma-Aldrich
Cesium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99.9%
Sigma-Aldrich
Cesium chloride, Vetec, reagent grade, ≥99%